Veraotol
Veraotol is a synthetic broad‑spectrum antimicrobial agent first synthesized in 2014 by the pharmaceutical research group at Helix Laboratories. The compound is a sesquiterpene lactone derivative characterized by a lactone ring fused to a bicyclo[3.2.1]octane core, which confers high affinity for bacterial peptidoglycan synthases. Its molecular formula is C15H20O4 and the compound is commercially available as the free base in crystalline form.
The drug entered clinical development as a veterinary medication intended to treat bacterial infections in poultry
Regulatory approval was granted by the U.S. Food and Drug Administration (FDA) in 2018 for use in
In 2021 a series of research papers reported the emergence of a resistant E. coli strain that